Action Point Financial Planning’s Sarepta Therapeutics SRPT Stock Holding History

Action Point Financial Planning’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18	Buy	+1	New	+$19	﹤0.01%	2775

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Action Point Financial Planning's SRPT Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 1 share worth $18. The stake represents ﹤0.01% of the portfolio and ranks #2775 among its holdings.

320 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Action Point Financial Planning held 1 share of Sarepta Therapeutics worth $18 as of Q2 2026.
Sarepta Therapeutics was a new Action Point Financial Planning position in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2775 holding.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.